Propecia Cost

Propecia Cost

glucose management. The American Diabetes Association (ADA) recommends a target HbA1C of less than 7 percent. When measured against the International Diabetes Federation (IDF) recommended target HbA1C of 6.5 percent or less, 18 percent of patients in the exenatide group achieved this level compared to 9 percent in the biphasic insulin aspart group. These findings were presented at the 42nd annual meeting of the European Association of the Study of Diabetes (EASD) in Copenhagen, Denmark. Patients on exenatide lost Propecia Cost an average of Propecia Cost 2.5 kilograms (5.5 pounds), while those receiving biphasic Propecia Cost insulin aspart gained an average of 2.9 kilograms (6.4 pounds). Weight gain is a common side effect of insulin therapy. In addition, exenatide reduced peak blood sugar levels after meals. Both treatments were associated with low rates of daytime and nighttime hypoglycemia (low blood sugar). "This comparator study demonstrates that exenatide has similar Propecia Cost blood glucose control to the conventional Propecia Cost treatment with insulin," said Professor Dr. Michael Nauck, Director of the Diabetes Centre in Bad Lauterberg, Germany, and a lead author of Propecia Cost the study. "These data show that exenatide, Propecia Cost without the inconvenience of dose titration, is a potential alternative to biphasic insulin aspart for the Propecia Cost treatment of Propecia Cost patients with type 2 diabetes Propecia Cost not adequately treated with metformin and a sulfonylurea, commonly used oral antidiabetic agents." Exenatide is the first in a new class of medicines known Propecia Cost as incretin mimetics and was Propecia Cost approved for use in the United States by the U.S. Food and Drug Administration in April 2005 Propecia Cost for the treatment of type Propecia Cost 2 diabetes. Exenatide Propecia Cost is injected twice daily. The U.S. is the first country that has received regulatory approval for exenatide. In late 2005, Propecia Cost Lilly submitted exenatide for approval in the European Union. Key Findings A1C reduction: * Both treatment groups achieved similar HbA1C reductions. Exenatide lowered HbA1C by 1.04 percent while biphasic Propecia Cost insulin aspart lowered HbA1C by 0.89 percent. * When measured against the target HbA1C of less than or equal to Propecia Cost 7 percent, 32 percent of patients in the exenatide group achieved this level compared to 24 percent in the biphasic insulin aspart group. * When measured against the target HbA1C of less than or equal to 6.5 Propecia Cost percent, 18 percent of patients in the exenatide group achieved this level compared to 9 percent Propecia Cost in the biphasic insulin aspart group. Glucose measurements: * As measured by patient self-glucose monitoring, exenatide reduced postprandial excursions, the rise of glucose after meals, following breakfast and dinner. Biphasic insulin aspart reduced mainly Propecia Cost pre-meal glucose. * The fasting blood glucose Propecia Cost at endpoint was decreased in patients treated with exenatide by 1.8 mmol/L and by 1.6 mmol/L in patients treated with biphasic insulin aspart. Weight change: * Weight Propecia Cost loss in the exenatide arm: Patients treated with exenatide experienced an average weight reduction of 2.5 kilograms (5.5 pou